Bupivacaine Effectiveness and Safety in SABER® Trial
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is a research study testing SABER-Bupivacaine (an experimental pain-relieving
medication). SABER-Bupivacaine is designed to continuously deliver bupivacaine, a common
local anesthetic, for a few days in order to treat local post-surgical pain.
The purpose of this study is to investigate safety (side effects) associated with the use of
SABER-Bupivacaine and how well it works in reducing pain and opioid-related side effects
following various kinds of abdominal surgeries.
Phase:
Phase 3
Details
Lead Sponsor:
Durect
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer Nycomed